West Leyden High School senior awaiting heart transplant graduates at Lurie Children's Hospital
It had all the makings of a typical graduation party. Blue and yellow streamers lined the room. Signs were posted on the walls that said 'Congrats Grad 2025,' 'You did it' and 'Made the grade.' In the back, there was a table full of Chips Ahoy and Oreos and even a cake that read 'Congratulations Taevion' in blue frosting.
Except, the party was held on the 22nd floor of Lurie Children's Hospital in honor of one of the hospital's patients: 18-year-old Taevion Norris. He had been attending West Leyden High School in Northlake when his senior year was suddenly interrupted in March due to heart failure, forcing him to spend the tail end of his final year of high school in the hospital.
But Norris refused to let his condition stop him from graduating on time — and succeeded. On Wednesday, Norris — wearing a blue cap and gown — was handed his diploma. Graduation music played in the background as he traversed from one end of the hospital hallway into the room of the ceremony.
'This is a very good day. Despite what he's going through, he was still able to graduate with his class,' Tainica Norris, Taevion's mother, said. 'It's good that he has a big crowd to see him achieve and accomplish one of his dreams and his goals, and just to be loved by everybody, because nobody knows what it's like to face what he has.'
In 2019, her eldest son was diagnosed with Duchenne muscular dystrophy, a neuromuscular condition where the body is unable to make dystrophin — a protein that helps keep muscles together. Without dystrophin, muscles in various parts of the body — such as the legs, arms and heart — get replaced with fibrous tissue. That can lead to bigger health issues, such as heart failure and losing the ability to walk.
Norris was in elementary school when one day, his mother received a phone call from the gym teacher.
'I was at work and he told me that I needed to get Taevion tested,' she recalled. 'And I'm like, 'What's going on?' He was like, 'I noticed that Taevion is not moving like he used to move, like his pace has slowed down.''
Norris was eventually referred to Dr. Katheryn Gambetta, a pediatric cardiologist at Lurie Children's Hospital. Gambetta said that Norris 'was around 12 or 13' when he was diagnosed and said that he was 'coming in at least every six months.'
'But he actually had heart dysfunction, probably when he was around 15, and then over time, that just got worse and worse,' Gambetta said. 'This is what we see — that heart dysfunction gets worse over time in boys and that the leading cause of death in boys who have Duchenne muscular dystrophy is due to heart failure.'
In the past year, Norris — who uses a wheelchair — had been admitted to the hospital multiple times, but his admittance about two months ago was unlike any of the others.
'Two months ago, he got really, really sick. He wasn't sleeping, he wasn't eating, he was just throwing up,' his mother recalled.
One morning, around 3 a.m., Norris called his mom and she found vomit everywhere in the bathroom, prompting her to call the ambulance. On March 11, Norris was admitted as an inpatient to the hospital, which he was not happy about.
'And he said, 'Mama, see I told you I didn't want to come here because I knew they were gonna keep me here. I want to go back to school,'' his mother said. 'I said, 'Taevion, it's either that or you're not gonna be here.''
The journey to get her son to graduation has not been an easy one.
'I stopped working because it started getting tough,' Norris' mother said. 'Kept going to the doctor, he kept getting more sicker, missing a lot of school, calling the school, let them know what's going on. It's just been hard.'
Norris' mother initially did not think that her son would be able to graduate on time while in the hospital. 'I thought it was gonna be a struggle, but he proved me wrong,' she said.
While it was not the first time Lurie Children's Hospital had a graduation for a student, the level of care from West Leyden High School that was put into helping Norris graduate was noted by the staff at Lurie Children's Hospital, making this one feel extra special.
Hana Herrick, a school services coordinator for Lurie Children's Hospital, said that she started working with Norris when he was admitted about two and a half months ago.
'Taevion can be very stoic at times, and he is very shy,' Herrick said. Finishing up school for Norris looked like a hybrid model, where he would have online classes with an instructor from his high school and Herrick by his side for additional in-person support.
Providing those online classes, Herrick said, was 'out of the norm.'
'Most schools don't do that for their students, so that was awesome,' Herrick said.
One of Herrick's favorite moments with him was when she told him that he had one task left, which was around the same time the two started working together: tackle George Orwell's novel 'Animal Farm.'
'The smile that came across his face was just so memorable,' Herrick said. 'And he was like, 'Whoa, really.' Like he couldn't believe it.'
Herrick said she was worried initially about how Norris was going to perceive the book, but those worries soon faded into the background. Not only did Norris finish reading the whole book, but he watched both movie adaptations and came up with rigorous reading comprehension questions.
As for next steps, Norris is on a waiting list for a heart transplant. According to Gambetta, he's been on the list for a heart transplant since May 1. Gambetta said she is hopeful that Norris will get his heart transplant soon, noting that he's been given an Impella ventricular assist device to allow him time to get a transplant. His family is also fundraising for a minivan through the Jett Foundation in order to make traveling together as a family easier.
Beyond the heart transplant, what career path Norris will pick is still up in the air, but his mother did note that he had previously considered being an NBA commentator.
'He wanted to be that. So I said, 'OK, well, you're gonna have to work for it. You're gonna have to learn how to do what they do and say what they say, and learn how to dress — well, he knows how to dress himself,' his mother said. 'So hopefully that might still be his pathway.'
But regardless of his journey, one thing was made clear as he was handed his diploma by Nick Polyak, superintendent of Leyden High School District 212.
'No matter where you go and what you do, you will always be a Leyden Eagle,' Polyak said.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
a day ago
- Forbes
The Triumphs And Trials Of Duchenne Gene Therapy
Today, the world stands at a crossroads in genetic medicine, as seen in Destiny's Child No Longer: Rewriting Genetic Fate on the topic. This story examines the progress and ongoing challenges in gene therapy for Duchenne muscular dystrophy, offering hope to families while underscoring the need for caution and continued research. Advances in gene therapy are beginning to change the narrative for children with genetic diseases like Duchenne muscular dystrophy. This rare disease has long meant progressive muscle weakness, loss of mobility, and shortened lives. For decades, families faced this diagnosis with limited options in the form of treatments that managed symptoms but did not alter the disease's inevitable trajectory. Duchenne muscular dystrophy primarily affects boys and begins in early childhood, usually between the ages of three and six. Children with this condition experience gradual muscle weakness, initially involving the hips and legs and later spreading to the shoulders and arms. Over time, the muscles deteriorate, making it difficult to walk, climb stairs, or lift objects. Most children lose the ability to walk during their teenage years. Eventually, vital muscles that support the heartbeat and breathing are affected, leading to severe complications. The root cause is a change in a single gene that prevents the body from making a crucial muscle protein. Without this protein, muscle cells are fragile and prone to rapid breakdown. Until recently, treatments could only slow the decline or help with symptoms, but they could not stop or reverse the disease. Gene therapy provides the body with the necessary instructions to produce a missing protein that is essential for muscle building. For Duchenne muscular dystrophy, this means helping muscle cells produce the proteins they need. Recent advances have made this possible, using tiny viral carriers to deliver the new gene. Providing treatment for the disease before significant muscle damage occurs is crucial. Clinical trials have shown promising outcomes. Some children who received gene therapy have regained muscle strength and improved their ability to walk. Although these milestones are preliminary, they are significant compared to traditional treatments and highlight the potential of genetic medicine. However, this progress has not come without risk. Earlier this year, Sarepta Therapeutics reported the first death linked to its gene therapy, Elevidys, used to treat Duchenne muscular dystrophy. The patient, a 16-year-old boy, died from acute liver failure following treatment. While liver injury is a known possible side effect of Elevidys and other gene therapies that use adeno-associated viruses as delivery vehicles, this was the first time a fatal case of acute liver failure had been observed among more than 800 patients treated in clinical trials or through commercial use. Further testing revealed that the patient had a recent cytomegalovirus infection, which can also damage the liver and may have contributed to the outcome. According to Sarepta, acute liver injury is highlighted in Elevidys' prescribing information, but the severity seen in this case had not previously been reported. This incident prompted renewed discussion about how to balance the urgent need for innovative treatments with the responsibility to ensure patient safety, especially as gene therapies become more widely used for treating rare diseases. The most extensive study to date of Elevidys, known as the EMBARK trial, provides a clearer picture of what this gene therapy can and cannot do for children with Duchenne muscular dystrophy. In this study, Elevidys did not meet its primary goal of showing a clear, measurable improvement in overall muscle function after one year compared to children who did not receive the therapy. However, there were encouraging signs: children who received Elevidys showed some improvements in specific activities, such as standing up from the floor and walking or running short distances. Tests also confirmed that the therapy helped their muscles produce the protein they are missing. The progress made in gene therapy for Duchenne muscular dystrophy is not just changing the outlook for this single disease. It is opening new doors for people living with many other inherited conditions. The scientific advances, regulatory lessons, and patient experiences from Duchenne gene therapy are informing how researchers and doctors approach similar treatments for other rare diseases. As more is learned about delivering genes safely and effectively, these breakthroughs could one day benefit a broader group of patients who currently have few or no treatment options. However, it is essential to remember that innovation must be accompanied by careful oversight and a steadfast commitment to safety. The complexities of gene delivery systems, immune responses to viral vectors, and the risk of off-target effects remain significant scientific hurdles that we must navigate with caution and responsibility. Real-world stories from families offer the most compelling evidence of gene therapy's potential. Some children who once faced a lifetime in a wheelchair have regained the ability to walk and play. These breakthroughs show how science can change lives. But progress is rarely smooth. Each step forward brings new questions and responsibilities. As we stand at the threshold of this new era, it is up to scientists, families, and society to work together, striking a balance between hope and caution, and innovation and safety. Only by learning from both our successes and setbacks can we build a future where a child's genetic fate is not predetermined.
Associated Press
a day ago
- Associated Press
WellBalance to Present Three Sessions at the 2025 IPPA World Congress in Brisbane, Australia
Includes Workshop to Train Coaches and Therapists to Use the WellBalance Model with Clients LAGUNA NIGUEL, CA / ACCESS Newswire / June 12, 2025 / WellBalance is honored to announce its selection to present three sessions at the upcoming International Positive Psychology Association's (IPPA) World Congress, taking place in Brisbane, Australia, July 2-5, 2025. Recognized as the premier global gathering of scientists and practitioners in the field of positive psychology, the IPPA World Congress spotlights cutting-edge approaches to promoting flourishing, resilience, and wellbeing across World Congress 2025 Among hundreds of submissions, three WellBalance abstracts were accepted across diverse formats - including one of only a few workshops offered at the Congress, to train coaches and therapists on the practical application of the WellBalance Model. This high-profile opportunity allows WellBalance to showcase the growing real-world impact of its evidence-based framework for personalized wellbeing design and will form the basis of future of certifications to use the WellBalance Assessment with clients. WellBalance's presentations include: 'This is a tremendous milestone for our team,' said Troy Norris, Founder and Principle Investigator of the WellBalance Institute for Positive Wellbeing. 'To be chosen for multiple presentations - and especially to lead a hands-on workshop for coaches and therapists - demonstrates the relevance, scientific rigor, and practical value of the WellBalance approach to advance the field of positive psychology toward real-world application.' The WellBalance Model and Assessment is a validated psychological measure of positive wellbeing, integrating feelings of wellbeing with lived experiences, to help individuals, coaches, and organizations identify meaningful growth areas and implement tailored, actionable wellbeing plans. The model has been highlighted in peer-reviewed publications in Frontiers in Psychology, Frontiers in Psychiatry, and Advances in the Psychology of Well-Being. This latest recognition by IPPA reinforces WellBalance's commitment to develop practical, science-based strategies to translate the latest science of positive psychology and wellbeing into actionable insights to create more flourishing lives, relationships and workplaces. By integrating validated wellbeing measures with a structured intervention framework, the WellBalance Model of Positive Wellbeing offers individuals, coaches, therapists and employers a practical and personal way to improve positive wellbeing. To learn more about the IPPA World Congress, visit: To explore the science behind the WellBalance Model, visit: Contact InformationTroy Norris Chief Wellbeing Officer SOURCE: WellBalance, LLC press release
Yahoo
2 days ago
- Yahoo
SpliceBio lands $135M for a new kind of eye gene therapy
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. SpliceBio, a Spanish biotechnology company working on next-generation gene therapies, said Wednesday it raised $135 million in a Series B round to advance its lead program in Stargardt disease into further clinical testing. The startup is built around a technology that's meant to overcome a key limitation of current gene therapies. Scores of gene therapy developers use adeno-associated viruses, or AAVs, to deliver genetic cargo into the body. But because of their small size, AAVs can't carry larger corrective genes, leaving many diseases out of reach or forcing companies to come up with creative solutions. One example is in Duchenne muscular dystrophy. Because of the large size of the gene coding for the muscle-protecting protein dystrophin Duchenne patients lack, several companies, like Sarepta Therapeutics, have developed gene therapies that make a shortened form. The approach comes with drawbacks, however, as a truncated version of the protein might not work as well as the original. SpliceBio has a different workaround. The company is using two separate AAVs to send pieces of a large gene into cells. Once inside, specially engineered splicing molecules help reassemble their cargo into full-length proteins. Stargardt disease, for example, is caused by mutations to the ABCA4 gene, which is too large to stuff into an AAV. SpliceBio says its method can help the body produce a functional version of the protein that gene produces. Its lead program, SB-007, is in a Phase 1/2 trial. SpliceBio isn't the only biotech pursuing this type of approach to treat Stargardt, an inherited eye condition that causes progressive vision loss. Another European company, AAVantgarde, has a similar type of program in early-stage testing. SpliceBio's technology is based on research conducted at Princeton University, where co-founder and CEO Miquel Vila-Perelló was studying protein design and engineering. Launched in 2014 under the name ProteoDesign, the biotech is also working on additional programs in ophthalmology, neurology and other undisclosed therapeutic areas. Its Series B round was co-led by EQT Life Sciences and Sanofi Ventures, and involved seven other backers including Roche Venture Fund, New Enterprise Associates and Novartis Venture Fund. "The support from such high-quality investors underscores the strength of our programs and our unique protein splicing platform and its potential to unlock gene therapies for diseases that remain untreatable today,' Vila-Perelló said in a statement. The company raised €50 million in a Series A round in 2022. Gene and cell therapy startups backed by the roughly two dozen investment firms BioPharma Dive tracks have secured a little over $1.1 billion in venture dollars so far in 2025. Half of those fundings have come in the form of 'megarounds' exceeding $100 million apiece, continuing an ongoing trend. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
